Sol-Gel And Searchlight Pharma Announce Licensing Agreements To Commercialize TWYNEO And EPSOLAY In Canada; Sol-Gel To Receive Up To $11M In Upfront Payments And Milestones Plus Additional Royalties From Low Double-Digits to High-Teens
Portfolio Pulse from Benzinga Newsdesk
Sol-Gel and Searchlight Pharma have entered into licensing agreements to commercialize TWYNEO and EPSOLAY in Canada. Sol-Gel will receive up to $11 million in upfront payments and milestones, plus additional royalties ranging from low double-digits to high-teens.
June 06, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sol-Gel signed licensing agreements with Searchlight Pharma to commercialize TWYNEO and EPSOLAY in Canada, receiving up to $11M in upfront payments and milestones, plus additional royalties.
The licensing agreements with Searchlight Pharma will provide Sol-Gel with additional revenue streams through upfront payments, milestones, and royalties. This partnership is expected to have a positive impact on Sol-Gel's stock price in the short term as it expands the company's market reach and potential earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100